skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Strategic industry insight

Contact us to get more information

Construct winning strategies that anticipate where value will lie. In Vivo’s in-depth analysis spans influential  deals, R&D, commercial and market access strategies. 

How it helps 

With In Vivo, you’ll benefit from:

  • Insight about the key players in the industry
  • In-depth coverage of company strategies
  • Expert analysis of deal making, R&D, commercial, market access and finance strategies and trends
  • Exclusive insider insight and thought leadership
  • Help with specific questions from our renowned Ask-the-Analyst™ service



How it works

Access mission-critical information via a simple-to-use interface. And if you need to need to find out more about developments or pharmaceutical industry trends to support presentations, proposals or business-critical decisions, you can access our worldwide network of expert analysts through our acclaimed Ask-the-Analyst™ service. 

Plus, you can identify threats and opportunities using our Execs on the Move feature, which tracks the company movements of senior executives.

What's included

Pharma Intelligence: latest

  • In Vivo

    Regular Acceptance Of Simulation Studies More Likely In 2020s

    By William Masters 17 Feb 2020

    Robotic_head

    Lyon, France-based Novadiscovery is developing a user-facing technology to run in silico studies, a method it expects to cut development costs and improve trial success rates. But acceptance of “new” data types is often a concern for drug developers, despite world-leading regulatory bodies stating their desire for 21st century approaches.

    Topic BioPharmaceutical

  • In Vivo

    A Tale Of Two Pipelines

    By Dennis Chang; Keith Flaherty; Uciane Scarlett 29 Jan 2020

    A_Tale_Of_Two_Pipelines_1

    Immuno-oncology has produced some exciting successes, but the field has become intensely crowded. Enormous resources are being poured into duplicative work and shaky hypotheses—overshadowing other pursuits in cancer research while producing limited results. It is time to re-evaluate how the sector should be pursuing innovation in cancer and how it can be smarter in its use of resources—financial investment, talent, bandwidth, patients and data.

    Topic Cancer Research

  • In Vivo

    ESG In 2020: Not A Tick-Box Exercise But A Strategic Opportunity

    By William Looney 29 Jan 2020

    ESG_In_2020_1

    The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.

  • In Vivo

    Bayer US Pharmaceuticals' Sebastian Guth: Designs On A New Decade

    By William Looney 27 Jan 2020

    Bayer_US_Pharmaceuticals_Sebastian_Guth

    Bayer’s ambitious campaign to reposition itself as a global leader in two complementary fields – health and nutrition – will face its toughest test in the US, with its highly litigious approach to product liability and a tendency to target pharmaceuticals as the source of the health system’s affordability and access problems.

  • In Vivo

    Outlook 2020 Report

    18 Dec 2019

    Outlook_2020_Content_Tile_Image

    Tap Outlook 2020’s essential coverage of medtech, R&D, clinical trials and regulation, manufacturing, and more with your extract from our most powerful report.

  • In Vivo

    Medtechs Enter The Decade of Digital, Consumers and Wellness

    By Ashley Yeo 11 Dec 2019

    Analysis

    For providers and medtech manufacturers alike, the decade ahead will be a time of coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market entry criterion, but companies will have to adapt to evolving health care delivery models. The stakes are implausibly high. Will they be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?

  • In Vivo

    Critical Insights into Market Access

    10 Dec 2019

    Critical Insights into Market Access

    Your key to refining your market access strategy with essential patient market access mini-mag and infographic from the experts at In Vivo.

  • In Vivo

    Brexit To And Fro Continues Into Fresh Decade

    By Ian Schofield 06 Dec 2019

    Analysis

    Three Brexit deadlines have come and gone, and the UK is still a member of the European Union. It will remain so until it agrees a withdrawal deal or leaves without one at the end of January 2020. Alternatively, it could secure yet another extension to the Article 50 period beyond January 31. Or it could decide not to leave at all.

    Topic Business Strategies Policy and regulation

  • In Vivo

    From US To EU: Young Biotechs Going It Alone

    By Jo Shorthouse 28 Nov 2019

    Analysis

    Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.

  • In Vivo

    MHealth And Research In Oncology

    By Niharika Dandamudi 20 Nov 2019

    Analysis

    The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices.”

    Topic Digital Health Personalized Medicine

  • In Vivo

    How Proximity Creates Partnerships

    By William Looney 08 Nov 2019

    Article

    Former Amgen R&D lead Sean Harper talks exclusively to In Vivo about his new role as a venture capitalist, joining veteran industry investor Beth Seidenberg as co-founder of Los Angeles-based Westlake Village BioPartners.

    Topic Business strategies Deal trends

  • In Vivo

    GSK's Hal Barron On R&D Progress At Two-Year Mark

    By Andrew McConaghie 01 Nov 2019

    GSKs_Hal_Barron_1

    Chief scientific officer at GSK, Hal Barron, talks about winning hearts and minds of 10,000 R&D employees, and adopting practices from acquired company Tesaro.

    Topic Business strategies Drug development landscape Research

  • In Vivo

    In Vivo Personalised Medicine

    18 Sep 2019

    In Vivo Personalised Medicine

    With more individualized treatments, such as cell and gene therapies, coming to market every day, In Vivo can keep you up to date on the diversity within clinical R&D, trials, the latest trends and the barriers that still exist within personalised medicine. We’ve pulled together a helpful infographic to summaries these changes.

    Topic Personalized Medicine

  • In Vivo

    Personalised Medicine: Treating the individual patient

    17 Sep 2019

    Personalised Medicine: Treating the individual patient

    With more individualized treatments, such as cell and gene therapies, coming to market every day, In Vivo can keep you up to date on the diversity within clinical R&D, trials, the latest trends and the barriers that still exist within personalised medicine. We’ve pulled together information covering the increasing focus of personalized medicine in clinical R&D and the future trends of precision medicine. 

    Topic Personalized Medicine

  • In Vivo

    Six of the Greatest Therapeutic R&D Challenges

    23 Aug 2019

    Six of the Greatest Therapeutic R&D Challenges

    Explore the six biggest therapeutic R&D challenges facing the industry today with a free infographic from In Vivo.  This snapshot view of the major issues facing R&D is packed with data and insights about everything from drug resistance to diagnostics challenges.  

    Topic Drug development landscape

Meet the team

Editor

William Looney

Editor, Executive Editor, In Vivo

USA

William Looney

William specializes in

  • Biopharma Pipeline Strategy
  • Biotech
  • Commercial Strategy
  • Market Access
  • Policy & Regulation

+40 year(s) experience

Editor

Cathy Kelly

Editor, Senior editor

Washington DC, USA

Cathy Kelly

Cathy specializes in

  • Policy & Regulation
  • Market Intelligence
  • Market Access
  • Pricing & Reimbursement

+39 year(s) experience

Management

Denise Peterson

Management, Editor In Chief, Pharma US

Washington DC, USA

Denise Peterson

Denise specializes in

  • Commercial Strategy
  • Policy & Regulation

+38 year(s) experience

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: